By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences has received notice from Nasdaq that it is not in compliance with a requirement to remain listed on the exchange.

In a document filed with the US Securities and Exchange Commission on Friday, Pressure Bio said that on Aug. 15, Nasdaq had notified it of its failure to comply with a listing requirement calling for a minimum bid price of $1 per share for 30 consecutive business days.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."